Key Disease Mechanisms Linked to Alzheimer’s Disease in the Entorhinal Cortex
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a chronic, neurodegenerative brain disorder affecting millions of Americans that is expected to increase in incidence with the expanding aging population. Symptomatic AD patients show cognitive decline and often develop neuropsychiatric symptoms due to the accumulation of insoluble proteins that produce plaques and tangles seen in the brain at autopsy. Unexpectedly, some clinically normal individuals also show AD pathology in the brain at autopsy (asymptomatic AD, AsymAD). In this study, SWItchMiner software was used to identify key switch genes in the brain’s entorhinal cortex that lead to the development of AD or disease resilience. Seventy-two switch genes were identified that are differentially expressed in AD patients compared to healthy controls. These genes are involved in inflammation, platelet activation, and phospholipase D and estrogen signaling. Peroxisome proliferator-activated receptor γ (PPARG), zinc-finger transcription factor (YY1), sterol regulatory element-binding transcription factor 2 (SREBF2), and early growth response 1 (EGR1) were identified as transcription factors that potentially regulate switch genes in AD. Comparing AD patients to AsymAD individuals revealed 51 switch genes; PPARG as a potential regulator of these genes, and platelet activation and phospholipase D as critical signaling pathways. Chemical–protein interaction analysis revealed that valproic acid is a therapeutic agent that could prevent AD from progressing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The DisGeNET knowledge platform for disease genomics: 2019 update
Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., & Furlong, L. I. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1021 · Cited by 2,639
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 1×
“Brain insulin resistance has been demonstrated in early AD through decreased IR, IRS-1, and PI3K signaling in mildly symptomatic as well as severely symptomatic patients [65].”
BackgroundNeuroligins and neurexins link synaptic function to cognitive disease
Südhof, T. C. (2008) · Nature · doi:10.1038/nature07456 · Cited by 1,849 · cited 1×
“Neurexins have been implicated in the development of many different cognitive diseases, from autism to schizophrenia [39].”
BackgroundJASPAR 2020: update of the open-access database of transcription factor binding profiles
Fornes, O., Castro-Mondragon, J. A., Khan, A., van der Lee, R., Zhang, X., Richmond, P. A., Modi, B. P., Correard, S., Gheorghe, M., Baranašić, D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1001 · Cited by 1,763
Alzheimer's Disease and the Amyloid-β Peptide
Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 2×
“Several researchers have labeled AD as “type 3 diabetes” due to the high prevalence of the disease amongst those who suffer from diabetes mellitus and insulin resistance [21].”
BackgroundDIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions
Karagkouni, D., Paraskevopoulou, M. D., Chatzopoulos, S., Vlachos, I. S., Tastsoglou, S., Kanellos, I., Papadimitriou, D., Kavakiotis, I., Maniou, S., Skoufos, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1141 · Cited by 1,135
Current understanding of Alzheimer’s disease diagnosis and treatment
Weller, J., & Budson, A. (2018) · F1000Research · doi:10.12688/f1000research.14506.1 · Cited by 1,083 · cited 1×
“Clinical symptoms include progressive worsening of memory impacting daily activities, leading to dependency and disability [5].”
BackgroundRetinoic acid in the development, regeneration and maintenance of the nervous system
Maden, M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2212 · Cited by 896
Lee (2019) · doi:10.1038/s12276-019-0299-y · Cited by 635
Khan, U. A., Liu, L., Provenzano, F. A., Berman, D. E., Profaci, C. P., Sloan, R., Mayeux, R., Duff, K. E., & Small, S. A. (2014) · Nature Neuroscience · doi:10.1038/nn.3606 · Cited by 561
Target analysis by integration of transcriptome and ChIP-seq data with BETA
Wang, S., Sun, H., Ma, J., Zang, C., Wang, C., Wang, J., Tang, Q., Meyer, C. A., Zhang, Y., & Liu, X. S. (2013) · Nature Protocols · doi:10.1038/nprot.2013.150 · Cited by 544
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Ge, X., Guo, M., Hu, T., Li, W., Huang, S., Yin, Z., Li, Y., Chen, F., Zhu, L., Kang, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.017 · Cited by 242
Beta‐amyloid deposition and the aging brain
Rodrigue, K. M., Kennedy, K. M., & Park, D. C. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9118-x · Cited by 230 · cited 1×
“Up to 20–30% of the aging population with intact cognition have Aβ deposition, with these individuals at higher risk of progressing to AD than those without Aβ [10].”
BackgroundInflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160488 · Cited by 215
Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis
Chou, R. C., Kane, M., Ghimire, S., Gautam, S., & Gui, J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0374-z · Cited by 194
History of Bipolar Disorder and the Risk of Dementia: A Systematic Review and Meta-Analysis
Diniz, B. S., Teixeira, A. L., Cao, F., Gildengers, A., Soares, J. C., Butters, M. A., & Reynolds, C. F. (2017) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.11.014 · Cited by 191
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models
Johansson, J. U., Woodling, N. S., Wang, Q., Panchal, M., Liang, X., Trueba-Saiz, A., Brown, H. D., Mhatre, S. D., Loui, T., & Andreasson, K. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77487 · Cited by 161 · cited 1×
“Increased prostaglandin activity decreases microglial activity, leading to the impaired clearing of misfolded proteins, improper regulation of inflammation, and impaired CNS tissue healing [46].”
BackgroundRisk factors for incident dementia after stroke and transient ischemic attack
Yang, J., Wong, A., Wang, Z., Liu, W., Au, L., Xiong, Y., Chu, W. W. C., Leung, E. Y. L., Chen, S., Lau, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.003 · Cited by 137
Chandra, S., Jana, M., & Pahan, K. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0054-18.2018 · Cited by 134
Venkataramani, V., Rossner, C., Iffland, L., Schweyer, S., Tamboli, I. Y., Walter, J., Wirths, O., & Bayer, T. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057836 · Cited by 133
Asymptomatic Alzheimers Disease: A Prodrome or a State of Resilience?
Driscoll, I., & Troncoso, J. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745348 · Cited by 130
Cortical Proteins Associated With Cognitive Resilience in Community-Dwelling Older Persons
Yu, L., Tasaki, S., Schneider, J. A., Arfanakis, K., Duong, D. M., Wingo, A. P., Wingo, T. S., Kearns, N., Thatcher, G. R. J., Seyfried, N. T., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1807 · Cited by 127 · cited 1×
“Further evidence of this trend was provided by a recent study, which showed that appropriate expression of CLPX1 promoted cognitive resilience in elderly patients and significantly diminished the risk of development of AD or any similar symptomatology [31].”
ResultCholesterol impairs autophagy-mediated clearance of amyloid beta while promoting its secretion
Barbero-Camps, E., Roca-Agujetas, V., Bartolessis, I., de Dios, C., Fernández-Checa, J. C., Marí, M., Morales, A., Hartmann, T., & Colell, A. (2018) · Autophagy · doi:10.1080/15548627.2018.1438807 · Cited by 125
Pharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113
Yang, Y.-W., Liou, S.-H., Hsueh, Y.-M., Lyu, W.-S., Liu, C.-S., Liu, H.-J., Chung, M.-C., Hung, P.-H., & Chung, C.-J. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.07.015 · Cited by 82
Lanke, V., Moolamalla, S. T. R., Roy, D., & Vinod, P. K. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00153 · Cited by 76
Zhou, Y., Deng, J., Chu, X., Zhao, Y., & Guo, Y. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-181053 · Cited by 71
Alterations in cholesterol metabolism–related genes in sporadic Alzheimer's disease
Picard, C., Julien, C., Frappier, J., Miron, J., Théroux, L., Dea, D., Breitner, J. C. S., & Poirier, J. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.018 · Cited by 60
Genetic Study of Neurexin and Neuroligin Genes in Alzheimer's Disease
Martinez-Mir, A., Initiative, A. D. N., González-Pérez, A., Gayán, J., Antúnez, C., Marín, J., Boada, M., Lopez-Arrieta, J. M., Fernández, E., Ramírez-Lorca, R., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122257 · Cited by 45
Wang, C., Zhao, F., Shen, K., Wang, W., Siedlak, S. L., Lee, H., Phelix, C. F., Perry, G., Shen, L., Tang, B., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12691 · Cited by 18 · cited 1×
“Increased tau levels are also correlated with disruption of SREBF2 signaling, leading to further neurodegeneration [81].”
BackgroundSynaptic Organizers in Alzheimer’s Disease: A Classification Based on Amyloid-β Sensitivity
Lee, A. K., Khaled, H., Chofflet, N., & Takahashi, H. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00281 · Cited by 14 · cited 1×
“NRXN1 has been found to interact with the Aβ plaques in AD leading to synaptic transmission impairment [41].”
Background
Cited by
Webber, E. K., Fivaz, M., Stutzmann, G. E., & Griffioen, G. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13065 · Cited by 50
Sex-specific transcriptional rewiring in the brain of Alzheimer’s disease patients
Santiago, J. A., Quinn, J. P., & Potashkin, J. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1009368 · Cited by 16
Self-citationNguyen, D. P. Q., Pham, S., Jallow, A. W., Ho, N.-T., Le, B., Quang, H. T., Lin, Y.-F., & Lin, Y.-F. (2024) · Scientific Reports · doi:10.1038/s41598-024-66693-8 · Cited by 14
Metadata
- Authors
- Bottero, V., Powers, D., Yalamanchi, A., Quinn, J. P., & Potashkin, J. A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-10
- Volume
- 22
- Issue
- 8
- Pages
- 3915
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3154185841
- Cited by
- 35
- References
- 38
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.